Abstract
In 2022, the World Health Organization (WHO) and International Consensus Classification (ICC) recognized TP53 as an entity-defining alteration in myeloid neoplasms, yet with differing criteria that could lead to discrepant diagnoses and affect clinical trial eligibility. We studied 67 patients with TP53 mutant myeloid neoplasms, reclassifying them using both criteria. While most cases fulfill the criteria for TP53 mutant defined entities, most discrepancies were found in cases with ≥20% blasts. Patients were stratified into three groups based on blast count (<10%, 10–19%, and ≥20%) which revealed comparable clinicopathologic features, genetic characteristics, and outcomes. Notably, patients with ≥10% blasts had shorter overall survival compared to those with <10% blasts (8.1 vs. 12.4 months; p = 0.03). This study is among the few to examine TP53 mutant myeloid neoplasms as a single entity and suggests that the 10% blast count threshold could serve as a gateway to a more harmonized classification for these patients.
Original language | English (US) |
---|---|
Pages (from-to) | 2151-2162 |
Number of pages | 12 |
Journal | Leukemia and Lymphoma |
Volume | 65 |
Issue number | 14 |
DOIs | |
State | Published - 2024 |
Bibliographical note
Publisher Copyright:© 2024 Informa UK Limited, trading as Taylor & Francis Group.
Keywords
- Acute myeloid leukemia
- Myelodysplastic syndrome
- Myeloid neoplasms
- TP53
- blast count
- copy number loss
- mutation
PubMed: MeSH publication types
- Journal Article